Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients
Yang Mao‐Draayer(University of Michigan), Fabrizio Giuliani(University of Alberta), Erin E. Longbrake(Yale University), Konstantin Balashov, Jason P. Mendoza(Biogen (United States)), Derrick Robertson(University of South Florida), Eris Bame(Biogen (United States)), Jennifer Lyons(Applied Biotechnology Institute), Oksana Mokliatchouk(Biogen (United States)), Amit Bar‐Or(University of Pennsylvania), James B. Lewin(Biogen (United States)), Nicholas Everage(Biogen (United States)), John Foley(Rocky Mountain Multiple Sclerosis Clinic), Kyle Smoot(Providence College), Ivan Božin(Biogen (Switzerland))
Cited by 6
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
|Nature Medicine|2007|1.8k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k